STOCK TITAN
  1. Home
  2. News
  3. COEP

Coeptis Therapeutics Holdings Inc. - COEP STOCK NEWS

Welcome to our dedicated page for Coeptis Therapeutics Holdings news (Ticker: COEP), a resource for investors and traders seeking the latest updates and insights on Coeptis Therapeutics Holdings stock.

Coeptis Therapeutics Holdings Inc is a biopharmaceutical company focused on developing cell therapy platforms for patients with cancer, autoimmune, and infectious diseases. The company's product portfolio includes multi-antigen CAR T technology known as SNAP-CAR, CD38-GEAR-NK cell therapy technology, and CD38-Diagnostic in vitro diagnostic for CD38-related cancers. Coeptis has strategic partnerships with Deverra Therapeutics, VyGen-Bio, the University of Pittsburgh, and the Karolinska Institutet to advance its innovative therapies. With a strong emphasis on research and development, Coeptis aims to revolutionize treatment paradigms and improve patient outcomes across various therapeutic areas.

News

Coeptis Therapeutics Announces Poster Data Presentation at American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting

Rhea-AI Summary

Coeptis Therapeutics Holdings, a biopharmaceutical company, will present data on the development of SNAP-CAR NK cells at the ASGCT Annual Meeting. The Company aims to revolutionize cancer treatment with a universal targeted cell therapy that eliminates the need for HLA matching.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.82%
Tags
none
-
News

Coeptis Therapeutics Congratulates Alexander Deiters, Professor at the University of Pittsburgh, on Receiving the 2024 Chancellor's Distinguished Research Award

Rhea-AI Summary
Coeptis Therapeutics congratulates Professor Deiters for receiving the University of Pittsburgh's 2024 Chancellor's Distinguished Research Award for his innovative CAR T cell therapy platform. The company aims to revolutionize oncology and autoimmune disorder treatments with SNAP-CAR technology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.78%
Tags
none
-
News

Coeptis Therapeutics Adds Autoimmune Indications to Exclusive License Agreement with University of Pittsburgh for SNAP-CAR T and SNAP-CAR NK

Rhea-AI Summary
Coeptis Therapeutics Holdings, Inc. expands its exclusive license agreement with the University of Pittsburgh to include autoimmune indications for its SNAP-CAR T and SNAP-CAR NK cell therapy platforms. The technology has the potential to target multiple antigens simultaneously, impacting autoimmune diseases and oncology indications.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.98%
Tags
none
News

Coeptis Therapeutics to Pursue Phase 2 Program Using Proprietary First-in-Class Allogeneic NK Cell Therapy for the Treatment of Viral Infections

Rhea-AI Summary
Coeptis Therapeutics Holdings, Inc. announces plans to pursue DVX201, a novel allogeneic stem cell expansion and directed differentiation platform of unmodified natural killer (NK) cell therapy, as an antiviral treatment for severe respiratory viral infections, including influenza, COVID-19, and respiratory syncytial virus (RSV). The therapy aims to replenish immune cells to help fight the infection and has shown promising results in Phase 1 clinical trials for patients with COVID-19 and hematological malignancies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.57%
Tags
clinical trial
-
News

Coeptis Therapeutics President and CEO Issues Letter to Shareholders Highlighting 2023 Accomplishments and Outlook for 2024

Rhea-AI Summary
Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) announced President and CEO Dave Mehalick's Letter to Shareholders, detailing the exclusive licensing agreement with Deverra Therapeutics Inc, the progress of DVX201 allogeneic NK cell therapy, and the company's vision for developing next-generation cell therapy technologies for cancer and infectious diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.65%
Tags
none
-
News

Coeptis Therapeutics to Present at the Emerging Growth Conference

Rhea-AI Summary
Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) announced that Dave Mehalick, President and CEO, will deliver a virtual presentation at the Emerging Growth Conference on December 6th, 2023. Coeptis is a biopharmaceutical company developing innovative cell therapy platforms for cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.35%
Tags
conferences acquisition
News

Coeptis Therapeutics Announces Research Demonstrating the Potential of SNAP-CAR T-cells to Reduce Tumor Burden and Growth in HER2 and CD20 Expressing Cancers Will be Presented at SITC 2023

Rhea-AI Summary
Coeptis Therapeutics announces research demonstrating the potential of the SNAP-CAR T-cell platform to target multiple antigens through combinatorial use of different adaptors. The research shows versatile antigen targeting abilities in vitro and in vivo, including potent and specific function, tumor reduction, and inhibition of tumor growth. The findings suggest the SNAP-CAR platform has vast potential for treating various cancers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.74%
Tags
none
-
News

Coeptis Therapeutics Announces $2 Million Private Placement

Rhea-AI Summary
Coeptis Therapeutics Holdings, Inc. has entered into a definitive agreement for a private placement of 2,000,000 shares of its common stock, with expected gross proceeds of $2,000,000. The company intends to use the net proceeds for working capital and general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.41%
Tags
none
-
News

Coeptis Therapeutics Expands License Agreement with University of Pittsburgh to Include SNAP-CAR NK Cell Technology

Rhea-AI Summary
Coeptis expands exclusive license agreement with University of Pittsburgh for SNAP-CAR technology platform in NK cells. Also obtains exclusive rights to negotiate acquisition of GEAR™ cell therapy and companion diagnostic platforms from VyGen Bio.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.61%
Tags
none
News

Coeptis Therapeutics to Participate in Panel at the BioFlorida Conference Discussing Emerging Cell and Gene Therapies

Rhea-AI Summary
Coeptis Therapeutics Holdings, Inc. to participate in panel on emerging cell and gene therapies at BioFlorida Conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.74%
Tags
conferences acquisition

FAQ

What is the current stock price of Coeptis Therapeutics Holdings (COEP)?

The current stock price of Coeptis Therapeutics Holdings (COEP) is $0.1415 as of December 20, 2024.

What is the market cap of Coeptis Therapeutics Holdings (COEP)?

The market cap of Coeptis Therapeutics Holdings (COEP) is approximately 5.6M.

What is Coeptis Therapeutics Holdings Inc focused on?

Coeptis is dedicated to developing cell therapy platforms for cancer, autoimmune, and infectious diseases.

What are the key products in Coeptis' portfolio?

The company's product portfolio includes SNAP-CAR multi-antigen CAR T technology, CD38-GEAR-NK cell therapy technology, and CD38-Diagnostic in vitro diagnostic.

Who are some of Coeptis' strategic partners?

Coeptis has strategic partnerships with Deverra Therapeutics, VyGen-Bio, the University of Pittsburgh, and the Karolinska Institutet.

What is Coeptis' goal in their research and development efforts?

Coeptis aims to revolutionize treatment paradigms and improve patient outcomes across various therapeutic areas.

Stock COEP logo
Coeptis Therapeutics Holdings Inc.

Nasdaq:COEP

COEP Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

COEP Stock Data

5.64M
31.46M
18.53%
4.28%
0.39%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
WEXFORD